O	0	6	Breast
O	7	14	density
O	15	22	changes
O	23	25	in
O	26	27	a
O	28	38	randomized
O	39	49	controlled
O	50	55	trial
O	56	66	evaluating
B-intervention	67	79	bazedoxifene
I-intervention	79	80	/
I-intervention	80	90	conjugated
I-intervention	91	100	estrogens
O	100	101	.

O	102	108	Breast
O	109	116	density
O	117	119	is
O	120	130	associated
O	131	135	with
O	136	138	an
O	139	148	increased
O	149	153	risk
O	154	156	of
O	157	163	breast
O	164	170	cancer
O	170	171	.

O	172	176	This
O	177	182	study
O	183	191	assessed
O	192	199	changes
O	200	202	in
O	203	215	mammographic
O	216	222	breast
O	223	230	density
O	231	236	after
O	237	239	24
O	240	246	months
O	247	249	of
O	250	259	treatment
O	260	264	with
O	265	277	bazedoxifene
O	278	279	(
O	279	282	BZA
O	282	283	)
O	283	284	/
O	284	294	conjugated
O	295	304	estrogens
O	305	306	(
O	306	308	CE
O	308	309	)
O	310	312	in
B-eligibility	313	327	postmenopausal
I-eligibility	328	333	women
O	333	334	.

O	335	339	This
O	340	343	was
O	344	346	an
O	347	356	ancillary
O	357	362	study
O	363	365	in
O	366	367	a
O	368	374	subset
O	375	377	of
O	378	396	nonhysterectomized
O	397	411	postmenopausal
O	412	417	women
O	418	426	enrolled
O	427	429	in
O	430	431	a
O	432	442	randomized
O	442	443	,
O	444	450	double
O	450	451	-
O	451	456	blind
O	456	457	,
O	458	465	placebo
O	465	466	-
O	466	476	controlled
O	476	477	,
O	478	481	and
O	482	488	active
O	488	489	-
O	489	499	controlled
O	500	505	phase
O	506	507	3
O	508	513	study
O	513	514	.

O	515	525	Treatments
O	526	535	evaluated
O	536	540	were
O	541	544	BZA
O	545	547	20
O	548	550	mg
O	550	551	/
O	551	553	CE
O	554	555	0
O	555	556	.
O	556	558	45
O	559	561	mg
O	561	562	,
O	563	566	BZA
O	567	569	20
O	570	572	mg
O	572	573	/
O	573	575	CE
O	576	577	0
O	577	578	.
O	578	581	625
O	582	584	mg
O	584	585	,
O	586	596	raloxifene
O	597	599	60
O	600	602	mg
O	602	603	,
O	604	607	and
B-control	608	615	placebo
O	615	616	.

O	617	622	Women
O	623	626	who
O	627	631	were
O	632	640	eligible
O	641	644	for
O	645	658	participation
O	659	661	in
O	662	665	the
O	666	675	ancillary
O	676	681	study
O	682	686	must
O	687	691	have
O	692	701	completed
O	702	704	24
O	705	711	months
O	712	714	of
O	715	724	treatment
O	725	728	and
O	729	733	have
O	734	744	mammograms
O	745	747	at
O	748	756	baseline
O	757	760	and
O	761	763	24
O	764	770	months
O	770	771	.

O	772	775	The
O	776	780	left
O	781	793	craniocaudal
O	794	799	views
O	800	804	from
O	805	809	each
O	810	819	mammogram
O	820	824	pair
O	825	829	were
O	830	839	digitized
O	840	843	and
O	844	852	analyzed
O	853	855	by
O	856	857	a
O	858	869	radiologist
O	870	873	who
O	874	877	was
O	878	885	blinded
O	886	888	to
O	889	898	treatment
O	899	902	arm
O	903	906	and
O	907	916	mammogram
O	917	921	date
O	921	922	.

O	923	926	The
O	927	934	percent
O	935	941	breast
O	942	949	density
O	950	953	was
O	954	964	determined
O	965	970	using
O	971	980	validated
O	981	989	software
O	989	990	.

O	991	1000	Mammogram
O	1001	1006	pairs
O	1007	1011	were
O	1012	1020	obtained
O	1021	1025	from
B-total-participants	1026	1029	507
O	1030	1039	evaluable
O	1040	1052	participants
O	1053	1054	(
O	1054	1058	mean
O	1059	1062	age
O	1063	1068	range
O	1068	1069	,
B-age	1070	1072	55
I-age	1072	1073	.
I-age	1073	1074	2
I-age	1074	1075	-
I-age	1075	1077	56
I-age	1077	1078	.
I-age	1078	1079	3
I-age	1080	1081	y
O	1081	1082	)
O	1082	1083	.

O	1084	1087	The
O	1088	1092	mean
O	1093	1100	changes
O	1101	1102	(
O	1102	1104	95
O	1104	1105	%
O	1106	1108	CI
O	1108	1109	)
O	1110	1112	in
B-outcome	1113	1125	mammographic
I-outcome	1126	1132	breast
I-outcome	1133	1140	density
I-outcome	1141	1145	from
I-outcome	1146	1154	baseline
I-outcome	1155	1157	to
I-outcome	1158	1160	24
I-outcome	1161	1167	months
O	1168	1172	were
O	1173	1183	comparable
O	1184	1189	among
O	1190	1196	groups
O	1197	1198	(
B-iv-cont-mean	1198	1199	-
I-iv-cont-mean	1199	1200	0
I-iv-cont-mean	1200	1201	.
I-iv-cont-mean	1201	1203	39
I-iv-cont-mean	1203	1204	%
O	1205	1206	[
O	1206	1207	-
O	1207	1208	0
O	1208	1209	.
O	1209	1211	69
O	1212	1214	to
O	1215	1216	-
O	1216	1217	0
O	1217	1218	.
O	1218	1220	08
O	1220	1221	]
O	1221	1222	,
B-iv-cont-mean	1223	1224	-
I-iv-cont-mean	1224	1225	0
I-iv-cont-mean	1225	1226	.
I-iv-cont-mean	1226	1228	05
I-iv-cont-mean	1228	1229	%
O	1230	1231	[
O	1231	1232	-
O	1232	1233	0
O	1233	1234	.
O	1234	1236	38
O	1237	1239	to
O	1240	1241	0
O	1241	1242	.
O	1242	1244	27
O	1244	1245	]
O	1245	1246	,
B-iv-cont-mean	1247	1248	-
I-iv-cont-mean	1248	1249	0
I-iv-cont-mean	1249	1250	.
I-iv-cont-mean	1250	1252	23
I-iv-cont-mean	1252	1253	%
O	1254	1255	[
O	1255	1256	-
O	1256	1257	0
O	1257	1258	.
O	1258	1260	54
O	1261	1263	to
O	1264	1265	0
O	1265	1266	.
O	1266	1268	08
O	1268	1269	]
O	1269	1270	,
O	1271	1274	and
B-cv-cont-mean	1275	1276	-
I-cv-cont-mean	1276	1277	0
I-cv-cont-mean	1277	1278	.
I-cv-cont-mean	1278	1280	42
I-cv-cont-mean	1280	1281	%
O	1282	1283	[
O	1283	1284	-
O	1284	1285	0
O	1285	1286	.
O	1286	1288	72
O	1289	1291	to
O	1292	1293	-
O	1293	1294	0
O	1294	1295	.
O	1295	1297	11
O	1297	1298	]
O	1299	1302	for
O	1303	1306	BZA
O	1307	1309	20
O	1310	1312	mg
O	1312	1313	/
O	1313	1315	CE
O	1316	1317	0
O	1317	1318	.
O	1318	1320	45
O	1321	1323	mg
O	1323	1324	,
O	1325	1328	BZA
O	1329	1331	20
O	1332	1334	mg
O	1334	1335	/
O	1335	1337	CE
O	1338	1339	0
O	1339	1340	.
O	1340	1343	625
O	1344	1346	mg
O	1346	1347	,
O	1348	1358	raloxifene
O	1359	1361	60
O	1362	1364	mg
O	1364	1365	,
O	1366	1369	and
O	1370	1377	placebo
O	1377	1378	,
O	1379	1391	respectively
O	1391	1392	)
O	1392	1393	.

O	1394	1399	These
O	1400	1410	reductions
O	1411	1415	from
O	1416	1424	baseline
O	1425	1429	were
O	1430	1443	statistically
O	1444	1455	significant
O	1456	1459	for
O	1460	1463	BZA
O	1464	1466	20
O	1467	1469	mg
O	1469	1470	/
O	1470	1472	CE
O	1473	1474	0
O	1474	1475	.
O	1475	1477	45
O	1478	1480	mg
O	1481	1484	and
O	1485	1492	placebo
O	1492	1493	.

O	1494	1497	The
O	1498	1504	effect
O	1505	1507	of
O	1508	1512	both
O	1513	1516	BZA
O	1516	1517	/
O	1517	1519	CE
O	1520	1525	doses
O	1526	1528	on
O	1529	1535	breast
O	1536	1543	density
O	1544	1547	was
O	1548	1557	generally
O	1558	1568	consistent
O	1569	1574	among
O	1575	1584	subgroups
O	1585	1590	based
O	1591	1593	on
O	1594	1597	age
O	1597	1598	,
O	1599	1603	body
O	1604	1608	mass
O	1609	1614	index
O	1614	1615	,
O	1616	1619	and
O	1620	1625	years
O	1626	1631	since
O	1632	1641	menopause
O	1641	1642	.

O	1643	1652	Treatment
O	1653	1657	with
O	1658	1661	BZA
O	1662	1664	20
O	1665	1667	mg
O	1667	1668	/
O	1668	1670	CE
O	1671	1672	0
O	1672	1673	.
O	1673	1675	45
O	1676	1678	mg
O	1679	1681	or
O	1682	1685	BZA
O	1686	1688	20
O	1689	1691	mg
O	1691	1692	/
O	1692	1694	CE
O	1695	1696	0
O	1696	1697	.
O	1697	1700	625
O	1701	1703	mg
O	1704	1707	for
O	1708	1710	24
O	1711	1717	months
O	1718	1721	did
O	1722	1725	not
O	1726	1732	affect
O	1733	1745	mammographic
O	1746	1752	breast
O	1753	1760	density
O	1761	1763	in
O	1764	1768	this
O	1769	1779	population
O	1780	1782	of
O	1783	1797	postmenopausal
O	1798	1803	women
O	1803	1804	.
